PMID- 11434729
OWN - NLM
STAT- MEDLINE
DCOM- 20010726
LR  - 20190619
IS  - 0003-4819 (Print)
IS  - 0003-4819 (Linking)
VI  - 135
IP  - 1
DP  - 2001 Jul 3
TI  - Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis 
      factor-alpha therapy.
PG  - 27-31
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) may have an important role in 
      the clinical exacerbation of sarcoidosis. OBJECTIVE: To treat sarcoidosis with 
      infliximab, a chimeric human-murine anti-human TNF-alpha monoclonal antibody. 
      DESIGN: Case report. SETTING: U.S. academic medical center. PATIENT: A 
      72-year-old woman with sarcoidosis presenting with severe protein-losing 
      enteropathy, hypoalbuminemia, and proximal myopathy who had not responded 
      adequately to corticosteroid therapy and whose clinical course was further 
      complicated by acute tubular necrosis and renal failure requiring long-term 
      hemodialysis. INTERVENTION: Intravenous infusion of infliximab, 5 mg/kg of ideal 
      body weight; infusion was repeated at 2 and 6 weeks. MEASUREMENTS: Clinical 
      response of enteropathic and myopathic symptoms and serum albumin level. RESULTS: 
      Enteropathic and myopathic symptoms resolved after infliximab therapy, and the 
      serum albumin level also improved. However, the clinical course was complicated 
      by the development of a hypercoagulable state associated with circulating 
      anticardiolipin antibodies, which prompted discontinuation of infliximab therapy. 
      CONCLUSIONS: Infliximab therapy was successful in a patient with sarcoidosis. 
      Tumor necrosis factor-alpha may be an important mediator of clinical disease in 
      sarcoidosis and could be an attractive target for therapeutic intervention. 
      However, infliximab may cause adverse effects associated with cytokine cascade 
      manipulation.
FAU - Yee, A M
AU  - Yee AM
AD  - Hospital for Special Surgery and New York Presbyterian Hospital, Weill Medical 
      College of Cornell University, New York, New York, USA.
FAU - Pochapin, M B
AU  - Pochapin MB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Serum Albumin)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
CIN - Ann Intern Med. 2002 Aug 20;137(4):296-7; author reply 296-7. PMID: 12186527
CIN - Ann Intern Med. 2002 Aug 20;137(4):296-7; author reply 296-7. PMID: 12186528
MH  - Acute Kidney Injury/complications/therapy
MH  - Aged
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Infliximab
MH  - Kidney Tubular Necrosis, Acute/complications
MH  - Lung Diseases/blood/complications/*drug therapy
MH  - Muscle Weakness/complications/drug therapy
MH  - Protein-Losing Enteropathies/complications/drug therapy
MH  - Renal Dialysis
MH  - Sarcoidosis/blood/complications/*drug therapy
MH  - Serum Albumin/metabolism
MH  - Thrombosis/chemically induced
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2001/07/04 10:00
MHDA- 2001/07/28 10:01
CRDT- 2001/07/04 10:00
PHST- 2001/07/04 10:00 [pubmed]
PHST- 2001/07/28 10:01 [medline]
PHST- 2001/07/04 10:00 [entrez]
AID - 200107030-00010 [pii]
AID - 10.7326/0003-4819-135-1-200107030-00010 [doi]
PST - ppublish
SO  - Ann Intern Med. 2001 Jul 3;135(1):27-31. doi: 
      10.7326/0003-4819-135-1-200107030-00010.